Alpha Teknova, Inc. (TKNO) Financial Statements
Industry: In Vitro & In Vivo Diagnostic Substances
In fiscal 2025, Alpha Teknova reported revenue of $40.5M, up 7.4% from $37.7M the year before. Net income was -$17.3M (a -42.6% net margin), or -$0.32 per diluted share. Gross margin was 33.2% and operating margin was -41.9%. Operating activities generated -$8.6M of cash, leaving -$9.8M of free cash flow. At fiscal year end, Alpha Teknova held $103.6M in total assets against $34.8M in total liabilities, including $5.9M of cash and equivalents.
Open the full interactive Alpha Teknova financials → Quarterly statements, key ratios, valuation history and price charts.
Alpha Teknova Key Stats
| Share Price | $8.22 |
|---|---|
| Market Cap | $440.9M |
| Revenue YoY Growth | +7.3% |
| 52-Week Range | $1.99 – $9.33 |
| Shares Outstanding | 53.6 million (basic, 2026 Q2) |
Alpha Teknova Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $36.9M | $41.4M | $36.7M | $37.7M | $40.5M |
| Cost of Goods Sold | $19.3M | $23.9M | $26.4M | $30.5M | $27.1M |
| Gross Profit | $17.6M | $17.5M | $10.3M | $7.2M | $13.4M |
| Operating Income | -$12.0M | -$49.7M | -$35.6M | -$26.1M | -$17.0M |
| Pre-Tax Income | -$12.6M | -$49.4M | -$37.1M | -$26.8M | -$17.2M |
| Income Tax | -$2.8M | -$1.9M | -$298,000 | -$88,000 | $58,000 |
| Net Income | -$9.8M | -$47.5M | -$36.8M | -$26.7M | -$17.3M |
| Diluted EPS | -$0.61 | -$1.69 | -$1.16 | -$0.57 | -$0.32 |
Alpha Teknova Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $10.5M | $10.0M | $11.1M | $12.2M |
| Net Income | -$4.3M | -$4.8M | -$4.6M | -$3.2M |
| Diluted EPS | -$0.08 | -$0.09 | -$0.08 | -$0.06 |
Alpha Teknova Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $87.5M | — | $28.5M | $3.7M | $5.9M |
| Current Assets | $101.2M | $61.1M | $45.7M | $42.8M | $34.5M |
| Total Assets | $166.5M | $152.3M | $128.6M | $118.8M | $103.6M |
| Current Liabilities | $7.7M | $10.9M | $8.9M | $11.2M | $7.5M |
| Total Long-Term Debt | $11.9M | $22.0M | $13.3M | $9.4M | $13.1M |
| Total Liabilities | $23.3M | $52.4M | $38.6M | $36.4M | $34.8M |
| Shareholders' Equity | $143.2M | $99.9M | $90.0M | $82.4M | $68.8M |
Alpha Teknova Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$9.1M | -$27.4M | -$18.8M | -$12.4M | -$8.6M |
| Cash From Investing | -$17.5M | -$28.1M | -$7.7M | -$27.3M | $10.7M |
| Cash From Financing | $110.8M | $10.3M | $12.8M | $14.9M | $151,000 |
| Free Cash Flow | -$28.9M | -$55.5M | -$26.7M | -$13.5M | -$9.8M |
Figures from Alpha Teknova's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Alpha Teknova financials page for every line item.
Alpha Teknova Company Profile
| Ticker | TKNO |
|---|---|
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Headquarters | Hollister, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001850902 |
Frequently Asked Questions
What was Alpha Teknova's revenue in fiscal 2025?
Alpha Teknova (TKNO) reported revenue of $40.5M for fiscal 2025.
What is Alpha Teknova's annual revenue history?
Alpha Teknova's annual revenue by fiscal year: 2021: $36.9M; 2022: $41.4M; 2023: $36.7M; 2024: $37.7M; 2025: $40.5M.
What was Alpha Teknova's net income in fiscal 2025?
Alpha Teknova reported net income of -$17.3M for fiscal 2025.
What was Alpha Teknova's earnings per share (EPS) in fiscal 2025?
Alpha Teknova's diluted EPS was -$0.32 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Alpha Teknova generate in fiscal 2025?
Alpha Teknova generated -$9.8M of free cash flow in fiscal 2025.
What was Alpha Teknova's revenue last quarter?
In its most recent reported quarter (2026 Q2), Alpha Teknova reported revenue of $12.2M.
How much debt does Alpha Teknova have?
Alpha Teknova reported $13.1M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Alpha Teknova are outstanding?
Alpha Teknova reported a weighted average of 53.6 million basic shares outstanding in 2026 Q2.
What is Alpha Teknova's market cap?
Based on its latest closing price, Alpha Teknova (TKNO) has a market capitalization of about $440.9M.
When does Alpha Teknova's fiscal year end?
Alpha Teknova's fiscal year end, as registered with the SEC, is December 31.
Where is Alpha Teknova headquartered?
Alpha Teknova lists its business address in Hollister, California in its SEC filings.
Alpha Teknova Competitors & Similar Companies
See all 15 In Vitro & In Vivo Diagnostic Substances companies →